메뉴 건너뛰기




Volumn 25, Issue 2, 2005, Pages 270-278

Cost-efficacy analysis of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors based on results of the STELLAR trial: Clinical implications for therapeutic selection

Author keywords

Acquisition cost; AWP; HMG CoA reductase inhibitor; LDL; Low density lipoprotein cholesterol; NCEP ATP III; Statin; STELLAR trial

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; STATIN;

EID: 13544273266     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.25.2.270.56946     Document Type: Article
Times cited : (12)

References (27)
  • 1
    • 0033945012 scopus 로고    scopus 로고
    • Pharmacoeconomic assessment of HMG-CoA reductase inhibitor therapy: An analysis based on the CURVES study
    • Hilleman DE, Heineman SM, Ford PA. Pharmacoeconomic assessment of HMG-CoA reductase inhibitor therapy: an analysis based on the CURVES study. Pharmacotherapy 2000;20:819-22.
    • (2000) Pharmacotherapy , vol.20 , pp. 819-822
    • Hilleman, D.E.1    Heineman, S.M.2    Ford, P.A.3
  • 2
    • 0032032592 scopus 로고    scopus 로고
    • Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)
    • Jones PH, Kafonek S, Lauora I, for the CURVES Investigators. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998;81:582-7.
    • (1998) Am J Cardiol , vol.81 , pp. 582-587
    • Jones, P.H.1    Kafonek, S.2    Lauora, I.3
  • 3
    • 0038645309 scopus 로고    scopus 로고
    • Comparison of atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial)
    • Jones PH, Davidson MH, Stein EA, et al. Comparison of atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). Am J Cardiol 2003;92:152-60.
    • (2003) Am J Cardiol , vol.92 , pp. 152-160
    • Jones, P.H.1    Davidson, M.H.2    Stein, E.A.3
  • 5
    • 0035897696 scopus 로고    scopus 로고
    • Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III)
    • Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001;285:2486-97.
    • (2001) JAMA , vol.285 , pp. 2486-2497
  • 6
    • 0032189666 scopus 로고    scopus 로고
    • Prevention of coronary heart disease in clinical practice: Recommendations of the second joint task force of European and other societies on coronary prevention
    • Wood D, De Backer G, Faegeman O, Graham I, Mancia G, Pyorola K. Prevention of coronary heart disease in clinical practice: recommendations of the second joint task force of European and other societies on coronary prevention. Eur J Heart 1998;19:1434-503.
    • (1998) Eur J Heart , vol.19 , pp. 1434-1503
    • Wood, D.1    De Backer, G.2    Faegeman, O.3    Graham, I.4    Mancia, G.5    Pyorola, K.6
  • 7
    • 0030603188 scopus 로고    scopus 로고
    • Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor therapy in the managed care era
    • Jacobson, TA. Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor therapy in the managed care era. Am J Cardiol 1996;78(suppl 6A):32-41.
    • (1996) Am J Cardiol , vol.78 , Issue.SUPPL. 6A , pp. 32-41
    • Jacobson, T.A.1
  • 8
    • 0032563770 scopus 로고    scopus 로고
    • Economic implications of lipid-lowering trials: Current considerations in selecting a statin
    • Farmer JA. Economic implications of lipid-lowering trials: current considerations in selecting a statin. Am J Cardiol 1998;82:26-31M.
    • (1998) Am J Cardiol , vol.82
    • Farmer, J.A.1
  • 9
    • 1542437305 scopus 로고    scopus 로고
    • Determinants of the cost-effectiveness of statins
    • Morrison A, Glassberg H. Determinants of the cost-effectiveness of statins. J Manag Care Pharm 2003;9:544-51.
    • (2003) J Manag Care Pharm , vol.9 , pp. 544-551
    • Morrison, A.1    Glassberg, H.2
  • 10
    • 0027243348 scopus 로고
    • Summary of the second report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II)
    • Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II). JAMA 1993;269:3015-23.
    • (1993) JAMA , vol.269 , pp. 3015-3023
  • 11
    • 0034723758 scopus 로고    scopus 로고
    • The lipid-treatment assessment project (L-TAP): A multicenter survey to evaluate the percentage of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol levels
    • Pearson TA, Laurora I, Chu H, Kafonek S. The lipid-treatment assessment project (L-TAP): a multicenter survey to evaluate the percentage of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol levels. Arch Intern Med 2000;160:459-67.
    • (2000) Arch Intern Med , vol.160 , pp. 459-467
    • Pearson, T.A.1    Laurora, I.2    Chu, H.3    Kafonek, S.4
  • 12
    • 0035897079 scopus 로고    scopus 로고
    • Assessing the results: Phase I hyperlipidemic outcomes in 27 health plans
    • Latts LM. Assessing the results: phase I hyperlipidemic outcomes in 27 health plans. AmJ Med 2001;110(suppl 6A):17S-23.
    • (2001) AmJ Med , vol.110 , Issue.SUPPL. 6A
    • Latts, L.M.1
  • 13
    • 0027154796 scopus 로고
    • Prevalence of high blood cholesterol among US adults. An update based on guidelines from the second report of the national cholesterol education program adult treatment panel
    • Sempos CT, Cleeman JI, Carroll MD, et al. Prevalence of high blood cholesterol among US adults. An update based on guidelines from the second report of the national cholesterol education program adult treatment panel. JAMA 1993;269:3009-14.
    • (1993) JAMA , vol.269 , pp. 3009-3014
    • Sempos, C.T.1    Cleeman, J.I.2    Carroll, M.D.3
  • 14
    • 0037031061 scopus 로고    scopus 로고
    • MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial
    • Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
    • (2002) Lancet , vol.360 , pp. 7-22
  • 15
    • 0037420492 scopus 로고    scopus 로고
    • Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian cardiac outcomes trial-lipid lowering arm (ASCOT-LLA): A multicentre randomised controlled trial
    • Sever PS, Dahlof B, Poulter NR, et al, for the ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian cardiac outcomes trial-lipid lowering arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58.
    • (2003) Lancet , vol.361 , pp. 1149-1158
    • Sever, P.S.1    Dahlof, B.2    Poulter, N.R.3
  • 16
    • 11144355354 scopus 로고    scopus 로고
    • Intensive versus moderate lipid lowering with statins after acute coronary syndromes
    • Cannon CP, Braunwald E, McCabe CH, et al, for the PROVE IT-TIMI 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504.
    • (2004) N Engl J Med , vol.350 , pp. 1495-1504
    • Cannon, C.P.1    Braunwald, E.2    McCabe, C.H.3
  • 17
    • 10744225301 scopus 로고    scopus 로고
    • Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: A randomized controlled trial
    • Nissen SE, Tuzeu EM, Schoenhagen P, et al, for the REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004;291:1071-80.
    • (2004) JAMA , vol.291 , pp. 1071-1080
    • Nissen, S.E.1    Tuzeu, E.M.2    Schoenhagen, P.3
  • 18
    • 3142729178 scopus 로고    scopus 로고
    • Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines
    • Grundy SM, Cleeman JI, Merz CNB, et al, for the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation 2004;110:227-39.
    • (2004) Circulation , vol.110 , pp. 227-239
    • Grundy, S.M.1    Cleeman, J.I.2    Merz, C.N.B.3
  • 19
    • 0242285687 scopus 로고    scopus 로고
    • The statin wars: Why AstraZeneca must retreat
    • Anonymous. The statin wars: why AstraZeneca must retreat [editorial]. Lancet 2003;362:1341.
    • (2003) Lancet , vol.362 , pp. 1341
  • 20
    • 0242361274 scopus 로고    scopus 로고
    • The statin wars
    • McKillop T. The statin wars [letter]. Lancet 2003;362:1498.
    • (2003) Lancet , vol.362 , pp. 1498
    • McKillop, T.1
  • 25
    • 0032842443 scopus 로고    scopus 로고
    • Choice of cost-effectiveness measure in the economic evaluation of cholesterol-modifying pharmacotherapy: An illustrative example focusing on the primary prevention of coronary heart disease in Canada
    • Morris S, Godber E. Choice of cost-effectiveness measure in the economic evaluation of cholesterol-modifying pharmacotherapy: an illustrative example focusing on the primary prevention of coronary heart disease in Canada. Pharmacoeconomics 1999;16:193-205.
    • (1999) Pharmacoeconomics , vol.16 , pp. 193-205
    • Morris, S.1    Godber, E.2
  • 26
    • 0036915307 scopus 로고    scopus 로고
    • Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia
    • Olsson AG, Istad H, Luurila O, et al, for the Rosuvastatin Investigators Group. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Am Heart J 2002;144:1044-51.
    • (2002) Am Heart J , vol.144 , pp. 1044-1051
    • Olsson, A.G.1    Istad, H.2    Luurila, O.3
  • 27
    • 0036910821 scopus 로고    scopus 로고
    • Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: A randomized, double-blind, 52-week trial
    • Brown WV, Bays HE, Hassman DR, et al, for the Rosuvastatin Study Group. Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial. Am Heart J 2002;144:1036-43.
    • (2002) Am Heart J , vol.144 , pp. 1036-1043
    • Brown, W.V.1    Bays, H.E.2    Hassman, D.R.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.